Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR1 | P11362 | 2/20 | 0.55 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.55 |
| ▸ | FGFR4 | P22455 | 1/20 | 0.55 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.55 |
| ▸ | KDR | P35968 | 1/20 | 0.55 |
| ▸ | RIPK2 | O43353 | 12/20 | 0.54 |
| ▸ | NOD2 | Q9HC29 | 12/20 | 0.54 |
| ▸ | ACVR1 | Q04771 | 9/20 | 0.54 |
| ▸ | CDK4 | P11802 | 1/20 | 0.50 |
| ▸ | CCND1 | P24385 | 1/20 | 0.50 |
| ▸ | CCND2 | P30279 | 1/20 | 0.50 |
| ▸ | CCND3 | P30281 | 1/20 | 0.50 |
| ▸ | SRC | P12931 | 4/20 | 0.46 |
| ▸ | WEE1 | P30291 | 3/20 | 0.46 |
| ▸ | BTK | Q06187 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4680305 | 0.92 | FGFR1 (0.56) | FGFR1FGFR2FGFR4FGFR3KDR | |
| SCHEMBL4676192 | 0.91 | FGFR1 (0.58) | FGFR1FGFR2FGFR4FGFR3KDR | |
| SCHEMBL4681349 | 0.87 | CDK4 (0.54) | FGFR1FGFR2FGFR4FGFR3KDR | |
| SCHEMBL4677377 | 0.85 | FGFR1 (0.61) | FGFR1FGFR2FGFR4FGFR3KDR | |
| SCHEMBL4676314 | 0.84 | FGFR1 (0.75) | FGFR1FGFR2FGFR4FGFR3KDR | |
| SCHEMBL4679629 | 0.84 | RIPK2 (0.66) | FGFR1FGFR2FGFR4FGFR3KDR | |
| SCHEMBL4678662 | 0.82 | FGFR1 (0.57) | FGFR1FGFR2FGFR4FGFR3KDR | |
| SCHEMBL4675870 | 0.82 | FGFR1 (0.61) | FGFR1FGFR2FGFR4FGFR3KDR | |
| SCHEMBL4679454 | 0.82 | FGFR1 (0.46) | FGFR1FGFR2FGFR4FGFR3KDR | |
| SCHEMBL6641442 | 0.81 | SRC (0.71) | FGFR1RIPK2NOD2ACVR1SRC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1195378-B1 | Pyridotriazines and pyridopyridazines | WARNER LAMBERT CO (US) | 2008-01-23 | — | — | EP | claimed |
| US-6683183-B2 | BICYCLIC HETEROCYCLES THAT INHIBIT CYCLIN-DEPENDENT KINASE OR TYROSINE KINASE ENZYMES, OR BOTH, FOR TREATMENT OF PROLIFERATIVE DISORDERS | WARNER-LAMBERT COMPANY | 2004-01-27 | — | — | US | claimed |
| US-20020061865-A1 | Pyridotriazines and pyridopyridazines | KRAMER JAMES BERNARD (US) | 2002-05-23 | — | — | US | claimed |
| EP-1195378-A1 | Pyridotriazines and pyridopyridazines | WARNER-LAMBERT COMPANY (US) | 2002-04-10 | — | — | EP | claimed |
| EP-1195378-B1 | Pyridotriazines and pyridopyridazines | WARNER LAMBERT CO (US) | 2008-01-23 | — | — | EP | disclosed |
| US-6683183-B2 | BICYCLIC HETEROCYCLES THAT INHIBIT CYCLIN-DEPENDENT KINASE OR TYROSINE KINASE ENZYMES, OR BOTH, FOR TREATMENT OF PROLIFERATIVE DISORDERS | WARNER-LAMBERT COMPANY | 2004-01-27 | — | — | US | disclosed |
| US-20020061865-A1 | Pyridotriazines and pyridopyridazines | KRAMER JAMES BERNARD (US) | 2002-05-23 | — | — | US | disclosed |
| EP-1195378-A1 | Pyridotriazines and pyridopyridazines | WARNER-LAMBERT COMPANY (US) | 2002-04-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020061865-A1 | Pyridotriazines and pyridopyridazines | CDK1, CDK4, CDK2 | FGFR1 194/4885FGFR2 694/4885FGFR4 403/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.